系统性红斑狼疮患者血浆IL-18的水平及意义

The Significance of Interleukin-18 Plasma Level in Patients with Systemic Lupus Erythematosus

目的:本研究通过检测系统性红斑狼疮(SLE)患者血浆白介素18(IL-18)的水平,分析探讨IL-18在SLE发病中可能的作用。方法:用酶联免疫吸附方法(ELISA)测定SLE组及对照组血浆IL-18的水平,比较不同疾病患者组间的差异。分析与C3、24h尿蛋白、抗ds-DNA抗体、血肌酐(Scr)及SLEDAI评分的相关性。结果:SLE活动组患者血浆IL-18水平高于SLE稳定组和正常对照组,SLE稳定组也高于正常对照组。并且IL-18在狼疮性肾炎(lupus nephritis,LN)组和无肾损伤组之间差异有显著性(P<0.05)。另外血浆IL-18水平与Scr、SLE疾病活动指数(SLEDAI)评分、24h尿蛋白、抗ds-DNA抗体密切相关。结论:SLE患者血浆IL-18可以作为预测SLE活动的指标,并且可能成为SLE药物治疗的靶点。

Objective： To detect plasma levels of IL-18 in patients with SLE and normal controls, and investigate the possible roles of IL-18 in the pathogenesis of SLE. Methods：The plasma levels of IL-18 were assayed in patients with SLE and compared with that of healthy controls. The differences in various SLE groups and its correlations with C3, anti-ds-DNA antibodies, 24-hour proteinuria, serum creatinine and the SLE disease activity of plasma IL-18 levels were studied. Results： Plasma levels of IL-18 were significantly higher in patients of active groups than that of inactive SLE groups and normal controls, Moreover, plasma levels of IL-18 were highly correlated with the levels of serum creatinine, SLEDAI, 24-hour proteinuria and anti-ds-DNA antibodies. Plasma levels of IL-18 in patients of LN were significantly higher than that in no-renal involvement group. Conclusion：The results suggest that plasma levels of IL-18 may be useful noninvase tool for monitoring the disease activity,and IL-18 may be the drug targets of biotherapy in patients with SLE.